Discounted Cash Flow
Boston Scientific Corp.
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $9.7b | $403.1m | $975.7m | 4.1% | $0.26 |
| 2017 | $10.5b (7.9%) | $120.8m (-70.0%) | $120.8m (-87.6%) | 1.1% (-72.2%) | $0.08 (-69.2%) |
| 2018 | $11.4b (8.6%) | $1.9b (1506.7%) | $160.3m (32.7%) | 17.0% (1380.0%) | $1.21 (1412.5%) |
| 2019 | $12.5b (9.3%) | $5.5b (181.3%) | $2.0b (1122.5%) | 43.8% (157.4%) | $3.38 (179.3%) |
| 2020 | $11.5b (-7.7%) | $-133.6m (-102.4%) | $-133.6m (-106.8%) | -1.2% (-102.6%) | $-0.08 (-102.4%) |
| 2021 | $13.8b (19.9%) | $1.1b (956.5%) | $1.5b (1244.3%) | 8.3% (814.2%) | $0.69 (962.5%) |
| 2022 | $14.7b (6.7%) | $745.7m (-34.8%) | $1.1b (-28.7%) | 5.1% (-38.9%) | $0.45 (-34.8%) |
| 2023 | $16.5b (12.3%) | $1.8b (144.5%) | $2.1b (91.0%) | 11.0% (117.8%) | $1.08 (140.0%) |
| 2024 | $19.5b (17.6%) | $2.2b (18.0%) | $3.1b (47.6%) | 11.1% (0.4%) | $1.26 (16.7%) |
| 2025 | $23.3b (19.9%) | $3.4b (56.4%) | $4.2b (38.3%) | 14.4% (30.5%) | $1.96 (55.6%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
SEC filings report in EUR. Values above are converted to USD for comparison with the US-listed share price.
Values abbreviated: b = billions, m = millions, k = thousands.
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Net debt deduction: —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.